Firefly Neuroscience Inc

This non-binding advisory proposal asks shareholders to approve the Company’s executive compensation program as disclosed in the proxy materials. Management seeks shareholder endorsement to validate its compensation philosophy, which comprises base salaries, discretionary cash bonuses, stock awards and option awards intended to attract and retain executive talent and align management incentives with long-term stockholder value. The Board and Compensation Committee will review the advisory vote results and consider them in future compensation decisions, although the vote will not be binding. The Company frames its program as balancing competitive pay with equity-based incentives to motivate performance and retention, and executives’ pay includes significant equity components to tie outcomes to shareholder returns. Given recent organizational changes and equity grants following the Merger and executive hires, management presents this advisory vote to confirm that shareholders accept the overall approach and levels of pay. The Board’s recommendation to vote ‘‘FOR’’ reflects its view that the program is appropriately structured to support growth, improve alignment with stockholders, and retain key executives during a critical stage of the Company’s development. Vote mechanics note that this is a non-routine matter for brokers, so street holders must provide instructions for their votes to count. While advisory, a strong affirmative vote would support continued use of equity-heavy incentives; a negative vote would trigger additional Board and Compensation Committee review and potential adjustments. The proposal sits in the context of increasing CAP (Compensation Actually Paid) tied to equity awards over the 2023–2025 period and the Board signals it will consider stockholder feedback in calibrating future awards.

Amendment No. 2 asks shareholders to approve a 2,000,000-share increase to the Company’s equity incentive plan reserve and to codify an updated evergreen formula for annual increases through 2035. Management argues the increase is necessary because current available shares (412,614 remaining) are insufficient given the Company’s compensation strategy and recent grants; the additional shares will permit future grants to recruit, retain, and motivate employees, directors and consultants without immediate need for further shareholder action. The proposal is pro-forma to satisfy exchange and tax qualification requirements (including enabling certain grants to qualify as ISOs under Section 422). The Board frames the request as a forward-looking capacity-building measure to preserve flexibility for equity awards that align management with long-term shareholder value. The principal counter-arguments a sophisticated analyst should consider include shareholder dilution from a relatively large increase (2,000,000 shares on a small outstanding base of ~15.06M shares as of the record date), the potential for misalignment if awards are granted liberally, and the absence of specific allocation guidelines or burn-rate limits in the amendment text. The amendment’s evergreen provision will cause the plan reserve to grow annually based on a percentage of outstanding shares, which can materially increase dilution over time; analysts should model potential dilution scenarios under reasonable growth and grant-rate assumptions. The Board’s unanimous recommendation and the discretionary nature of future grants mean shareholders are being asked to trust governance processes (Compensation Committee oversight) to balance dilution and retention needs. If approved, the Company will avoid repeated frequent share-request solicitations, but investors should monitor future disclosure of actual grant practices, director/NEO awards, and share usage metrics. Overall, the proposal is typical for early-stage public companies seeking operating flexibility, but investors should weigh the trade-off between dilution and the Company’s ability to execute its hiring and incentive plans.

The Company requests shareholder approval to amend its Certificate of Incorporation to reduce the authorized share count from 5,001,000,000 to 101,000,000 (100,000,000 Common, 1,000,000 Preferred) primarily to lower Delaware franchise tax liability. Management’s stated rationale is cost reduction: Delaware franchise taxes are in part a function of authorized shares, so a large authorized-share count increases recurring franchise tax expense; the Board expects the reduced authorized cap to materially lower that tax. The Board asserts the reduced cap remains sufficient for foreseeable needs (financings, equity-plan issuances, strategic transactions) and notes it can seek stockholder approval later to increase authorization if required. A skeptical analyst should weigh the tax savings against the loss of flexibility — significant corporate actions may require rapid issuance of shares and would necessitate a shareholder vote to increase authorization, potentially delaying time-sensitive transactions. The amendment does not affect outstanding shares, par value, or rights of existing holders, but reduces unissued share availability and therefore could constrain future financing or M&A flexibility absent additional approvals. The vote requires a majority of voting power of all outstanding shares voting together as one class, meaning abstentions and broker non-votes count effectively as votes against. The Board’s unanimous recommendation reflects a governance choice to prioritize near-term cash savings; investors should monitor whether future requests to reauthorize shares arise and the timing/terms if they do. Overall, the measure is a conventional corporate housekeeping action with tangible tax benefits but with trade-offs around agility for future capital actions.

This proposal requests authority to adjourn or postpone the Annual Meeting to solicit additional proxies if there are insufficient votes to approve one or more proposals at the meeting. Management views this as a procedural mechanism to enable full deliberation and to provide additional time for outreach to stockholders whose votes are needed to approve substantive matters, thereby avoiding a potentially premature defeat of proposals that management and the Board believe are in the Company’s and stockholders’ interests. The practical effect is to authorize proxies to vote to adjourn the meeting rather than immediately holding a vote that could fail due to lack of quorum or insufficient affirmative votes on specific items. The proposal is standard corporate practice; its primary governance risk is that it could be used to delay votes while additional solicitation continues, which some investors view as management entrenchment if used repeatedly. However, the Company frames the proposal as protective of stockholder value because it allows more time to solicit votes on significant, potentially transformative matters. The approval threshold is a simple majority of votes cast, and this proposal is treated as a routine matter for brokers which may permit broker votes. If approved, it gives the Board discretion to adjourn for further solicitation, but the Board retains a fiduciary duty to act in stockholders’ best interests. For analysts, the key considerations are frequency of use, transparency about reasons for adjournments, and whether adjournments have materially altered outcomes in the Company’s favor.